InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 20 September 2024

MAHOGANY: This study is comparing the effectiveness of different targeted therapy treatments in people with relapsed or refractory follicular lymphoma and marginal zone lymphomaA Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Clinical summary

Summary

This study is recruiting people with relapsed or refractory Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL), and is testing different treatments depending on which disease you have.

People with Follicular Lymphoma will be randomly allocated to either the Experimental or Active Comparator Arms.

  • In the Experimental Arm, people with FL will receive a combination of targeted therapies: zanubrutinib and obinutuzumab. Once they have finished receiving the combination treatment, participants will continue receiving zanubrutinib alone.
  • In the Active Comparator Arm, people with FL will receive targeted therapy (rituximab) plus lenalidomide, which is a drug that modifies the response of the immune system.

People with Marginal Zone Lymphoma will be randomly allocated to either an Experimental or Active Comparator Arm.

  • In the Experimental Arm, people with MZL will receive combination targeted therapy (zanubrutinib + rituximab). Once they have finished receiving the combination treatment, participants will continue receiving zanubrutinib alone.
  • In the Active Comparator Arm, people with MZL will receive targeted therapy (rituximab) plus lenalidomide, which is a drug that modifies the response of the immune system.

Conditions

This trial is treating patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma

Cancer

Blood Cancers Haematological

Age

People18+

Phase

III

Trial Acronym

MAHOGANY

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

BeiGene Australia Pty Ltd

Scientific Title

A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Eligibility

Inclusion

  • Histologically confirmed grade 1-3a FL or MZL
  • Previously received ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy
  • Need for systemic therapy for FL or MZL
  • Measurable disease by computed tomography or magnetic resonance imaging
  • Adequate bone marrow, liver and renal function

Exclusion

  • Transformation to aggressive lymphoma
  • Requiring ongoing need for corticosteroid treatment
  • Clinically significant cardiovascular disease
  • Prior malignancy within the past 2 years
  • Active fungal, bacterial, and/or viral infection that requires systemic therapy

Inclusion

  • You have had treatment, but your cancer has come back.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You are able to swallow medication by mouth.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Cancer Connect

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Get support

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

More info for carers

CloseReport inaccuracy

Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.

HelpThis verification step helps prevent fraudulent transactions from automated software.
Submitting ... Please wait

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.